博爱新开源医疗科技集团股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《中华人民共和国公司法》和《公司章程》有关规定，经博爱新开源医 疗科技集团股份有限公司（以下简称"公司"）第五届董事会第十九次会议审议通 过，决定召开 2025 年第一次临时股东大会。现将有关事项通知如下： 一、召开会议的基本情况 1、会议届次：2025年第一次临时股东大会 2、召集人：公司董事会 证券代码：300109 证券简称：新开源 公告编号：2025-045 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业 板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》 的有关规定。 4、会议召开时间： 现场会议时间：2025年12月22日（星期一）下午14:00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为2025 年12月22日9:15-9:25,9:30-11:30,13:00-15:00；通过深圳证券交易 ...

证券代码：300109 证券简称：新开源 公告编号：2025-042 博爱新开源医疗科技集团股份有限公司 第五届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本次会议由公司监事会主席阎重朝先生主持，应出席监事 3 名，实际出席监 事 3 名。本次会议的召集和召开程序符合《公司法》和《公司章程》的有关规定。 经与会监事审议，表决通过以下议案： 二、监事会会议审议情况 （一）审议并通过《关于修订<公司章程>的议案》 根据《中华人民共和国公司法》（以下简称"公司法》"）《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等法律法规、规范性文件的最新规定，结合公司实际 情况，公司董事会下设的审计委员会将行使《公司法》规定的监事会的职权，《博 爱新开源医疗科技集团股份有限公司监事会议事规则》相应废止，《公司章程》 中相关条款亦作出相应修订。 上述事项提请股东大会授权公司法定代表人及其授权代表办理《公司章程》 的工商变更登记备案事宜。本次《公司章程》中有关条款的修订内容，以市场监 ...

（文章来源：证券日报） 证券日报网讯 12月2日，新开源在互动平台回答投资者提问时表示，截至2025年11月28日收市，公司股 东户数合并约为19880户。 ...

Group 1 - The company holds an 11.1111% stake in New Anjin [2] - New Anjin's individualized drug injection P01 is currently advancing clinical trials as planned [2]

Group 1 - The core point of the article is the progress of clinical trials for Nuanzin's personalized drug injection P01, which is the world's first personalized tumor neoantigen peptide vaccine approved by both Chinese and American drug regulatory authorities [2][3] - New Source (300109.SZ) holds an 11.1111% stake in Nuanzin and has confirmed that the clinical trials for P01 are progressing as planned [2] - The company emphasizes its commitment to timely, fair, and significant information disclosure in compliance with legal obligations [2]

（编辑 姚尧） 证券日报网讯 11月25日晚间，新开源发布公告称，截至本公告日持有博爱新开源医疗科技集团股份有 限公司（以下简称"公司"或"本公司"）股份525，000股（占本公司总股本比例0.11%）的董事、高级管 理人员于江涛先生计划在本公告披露之日起15个交易日后的3个月内（2025年12月17日至2026年03月16 日，但窗口期不减持）以集中竞价交易方式减持公司股份不超过（含）130，000股（占公司总股本的比 例不超过0.03%）。截至本公告日持有公司股份352，500股（占本公司总股本比例0.07%）的高级管理 人员邢小亮先生计划在本公告披露之日起15个交易日后的3个月内（2025年12月17日至2026年03月16 日，但窗口期不减持）以集中竞价交易方式减持公司股份不超过（含）88，000股（占公司总股本的比 例不超过0.02%） ...

Core Viewpoint - The announcement details the planned share reduction by two senior executives of Xin Kai Yuan (300109.SZ), indicating a potential shift in insider sentiment towards the company's stock [1] Group 1: Share Reduction Plans - Director Jiang Tao plans to reduce his holdings by up to 130,000 shares, which represents no more than 0.03% of the company's total share capital, within a specified window from December 17, 2025, to March 16, 2026, excluding any reduction during the trading window [1] - Senior executive Xing Xiaoliang intends to reduce his holdings by up to 88,000 shares, accounting for no more than 0.02% of the company's total share capital, also within the same trading window [1]

Group 1 - The company New Open Source (SZ 300109) announced that two executives plan to reduce their shareholdings within three months, with one executive intending to sell up to 130,000 shares (0.03% of total shares) and another up to 88,000 shares (0.02% of total shares) [1] - As of the announcement date, the company holds approximately 520,000 shares (0.11% of total shares) by one executive and 352,500 shares (0.07% of total shares) by another [1] - For the first half of 2025, the company's revenue composition is 89.56% from fine chemicals and 10.44% from medical services [1] Group 2 - The company's market capitalization is reported to be 8.7 billion yuan [2] - A related company, identified as 688496, is under investigation by the Securities Regulatory Commission due to a significant loss exceeding 100 million yuan shortly after its listing, with its main customer reducing procurement [2]

Core Viewpoint - The company announced that two senior executives plan to reduce their shareholdings due to personal financial needs, with specific limits on the number of shares to be sold and assurances that this will not affect the company's control or governance structure [1] Group 1: Shareholding Reduction Plans - Executive Jiang Tao plans to reduce his holdings by up to 130,000 shares, representing no more than 0.03% of the total share capital, within three months after a 15 trading day period from the announcement [1] - Executive Xing Xiaoliang intends to reduce his holdings by up to 88,000 shares, accounting for no more than 0.02% of the total share capital, also within three months after the 15 trading day period [1] Group 2: Current Shareholding Status - As of the announcement date, Jiang Tao holds 525,000 shares, which is 0.11% of the total share capital [1] - As of the announcement date, Xing Xiaoliang holds 352,500 shares, which is 0.07% of the total share capital [1] Group 3: Conditions and Implications - The share reduction plans are based on personal financial needs and the shares are sourced from equity incentives [1] - The planned reductions do not violate any relevant commitments and will not lead to changes in company control or affect its governance structure and ongoing operations [1]

Core Points - The company announced that its board member and senior vice president, Yu Jiangtao, holds 525,000 shares, accounting for 0.11% of total shares, and plans to reduce his holdings by up to 130,000 shares (0.03%) through centralized bidding from December 17, 2025, to March 16, 2026 [1] - The company’s board secretary and vice president, Xing Xiaoliang, holds 352,500 shares, representing 0.07% of total shares, and intends to reduce his holdings by up to 88,000 shares (0.02%) during the same period [1]